Experimental formulation could be future for fast-acting insulin
The novel formulation hit peak activity at nine minutes, less than half the time taken for a commercially available formulation.
List view / Grid view
The novel formulation hit peak activity at nine minutes, less than half the time taken for a commercially available formulation.
The team used cryogenic electron microscopy (cryo-EM) to show how the 10E8 antibody interacts with the HIV’s fusion protein to neutralise the virus.
Researchers have created a method to promote the production of new antibiotic or antiparasitic compounds from the genomes of actinobacteria.
A team of researchers has analysed how SARS-CoV-2 hijacks the proteins in its host cells to aid replication and infect nearby cells.
Researchers have hypothesised that treatments targeting the downregulation of AhRs and IDO1 genes could reduce severity of COVID-19 infection.
A group of researchers has used locked nucleic acid gapmer antisense oligonucleotides to treat facioscapulohumeral muscular dystrophy in cells and mice.
A study of blood samples from COVID-19 patients has allowed a team to reveal six molecular targets that could be used to develop treatments for the virus.
Researchers grew large crystals and used an X-ray machine with a less intense beam to elucidate the structure of the SARS-CoV-2 main protease at room temperature.
Scientists have revealed that four molecules found in the Ceramaster patagonicus starfish show potency against cancer in cell lines.
Researchers have synthesised three oligonucleotide inhibitor molecules which stopped seizures in mouse models, making them potential epilepsy drugs.
A study has revealed 68 protein-coding genes associated with risk of severe COVID-19, nine of which are targeted by drugs currently in clinical trials.
Over the past year, BellBrook Labs has leveraged its Transcreener HTS Assay technology to build enabling products and services focusing on innate immunity targets.
After virtually screening 640 existing drug compounds, researchers have revealed that PC786 potently targets several SARS-CoV-2 receptors, making it a candidate to fight COVID-19.
By administering a one-time PTB antisense oligonucleotide therapy to mice, researchers observed an increase in neurons and elimination of Parkinson's from the models.
New research has found that of the 718 pipeline drugs associated with COVID-19, 70 percent are currently in the discovery or pre-clinical stages.